-
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
•
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be…
-
NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings
•
The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts for 11 drug varieties, impacting 47 products in total. The updates include changes to sections on adverse reactions, contraindications, and precautions. Marketing Authorization Holders (MAHs) are mandated to update the package inserts and labels within…
-
Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma
•
Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196) has dropped plans to sell its stake in Indian pharmaceutical firm Gland Pharma Ltd (NSE: GLAND). This decision comes after Fosun was reported in November 2022 to have been considering the sale of…
-
LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product
•
Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with South Korea-headquartered LegoChem Biosciences, Inc. Under this agreement, the two companies will leverage LaNova’s antibody assets and LCB’s antibody-drug conjugate (ADC) technology platform to develop an innovative ADC product. LaNova Medicines: A Clinical-Stage R&D CompanyEstablished…
-
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced plans to enter into an exclusive licensing agreement with Shenyang 3SBio Co., Ltd. The deal grants 3SBio extensive rights, including development, regulatory, manufacturing, use, sales, export, and import, for its antitumor programs 602, 609, 705,…
-
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings for its PCSK9 monoclonal antibody (mAb) ongericimab (JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia to the National Medical Products Administration (NMPA). Phase III and II Clinical Studies Support FilingsOngericimab is currently in…
-
Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages
•
The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price negotiations for provincial stock drugs on April 27. The initiative involves 18 shortage drugs, including pralidoxime, deslanoside, promethazine, and agkistrodon halys snake antivenom, with the participation of 30 manufacturers such as Beijing China Resources Hi-Tech…
-
Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor, has entered into a partnership with Japanese firm Chugai Pharmaceutical to jointly establish an angina pectoris center. This collaboration aims to integrate medical expertise with technological innovation to enhance coronary heart disease management. Advancing Coronary…
-
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing in its Phase III registrational clinical trial (CTR20212816) for BBM-H901, a gene therapy for hemophilia B. The therapy is developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., a wholly owned subsidiary of BBM.…
-
Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai Escugen, aimed at advancing the research, development, and manufacturing of antibody-drug conjugates (ADCs). The collaboration extends from late clinical development through to the commercialization phase, with financial details undisclosed. Leveraging Tot Bio’s Expertise in ADC…
-
Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its US partner Visus Therapeutics Inc., has published positive topline results from the pivotal Phase III BRIO-I trial. BRIO-I Trial Success and Regulatory MilestonesThe BRIO-I trial successfully met the pre-specified primary study endpoints that were agreed…
-
Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
•
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts. Company Background…
-
Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch
•
US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical Technology Co. The agreement grants Liuqiang exclusive rights to develop and commercialize Sable’s microneedle patch, which includes SBL-003 and SBL-004, in Greater China. The patch is designed for targeted aesthetic fat reduction through a process…
-
Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China
•
Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment of USD 40.6 million in a new factory located in Suzhou. The facility will specialize in the manufacturing of endoscope products, reflecting the company’s commitment to the Chinese market. Growing Significance of the Chinese Market…
-
Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software
•
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The funds raised will be directed towards the research and development of new products and the globalization of the company’s operations. Company Background and Pharmaceutical Safety ServicesFounded in…
-
Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions
•
Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk control solutions for medical and commercial insurance, has reportedly raised RMB 300 million (USD 43.39 million) in a Series C financing round. The round was led by China Taiping Insurance Group Company’s healthcare funds, with…
-
Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics
•
Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million). Company Background and Product…
-
Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has received marketing approval from Bolivia’s State Agency of Drugs and Health Technologies (AGEMED) for its insulin glargine product, which comes in a pre-filled format. Insulin Glargine: A Long-Acting Insulin AnalogueInsulin glargine is a long-acting insulin…
-
Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement
•
China-based Rainmed Medical Limited has announced that it has received market approval from the National Medical Products Administration (NMPA) for its innovative coronary artery function measurement system, the caIMR system. Microcirculatory Resistance Index (IMR) and Its Clinical SignificanceThe microcirculatory resistance index (IMR) is a quantitative method used to evaluate the…
-
WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1
•
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first quarter of 2023, recording RMB 8.964 billion (USD 1.29 billion) in revenues, marking a 5.77% year-on-year (YOY) increase, and net profits of RMB 2.168 billion (USD 313.6 million), up 31.97% YOY. Client Expansion and…
